Rick Bienkowski
Stock Analyst at Ladenburg Thalmann & Co.
(0.16)
# 4,637
Out of 5,005 analysts
49
Total ratings
25.7%
Success rate
-19.2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Rick Bienkowski
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EDIT Editas Medicine | Initiated Coverage: Buy | $6 | $2.51 | +139.04% | 14 | Aug 18, 2026 | |
| PMVP PMV Pharmaceuticals | Reiterated: Buy | $3 | $1.36 | +120.59% | 2 | Aug 17, 2026 | |
| TTRX Turn Therapeutics | Reiterated: Buy | $16 | $13.04 | +22.70% | 1 | Aug 13, 2026 | |
| CAPR Capricor Therapeutics | Downgraded: Hold | n/a | $8.71 | - | 1 | Jul 30, 2026 | |
| BEAM Beam Therapeutics | Reiterated: Buy | n/a | $24.23 | n/a | 13 | Aug 19, 2025 | |
| NTLA Intellia Therapeutics | Reiterated: Buy | $65 | $11.42 | n/a | 6 | May 29, 2025 | |
| LEGN Legend Biotech | Reiterated: Buy | $83 → $55 | $18.62 | n/a | 4 | May 13, 2025 | |
| CRBU Caribou Biosciences | Initiated Coverage: Hold | n/a | $1.23 | n/a | 1 | Nov 8, 2023 | |
| LON: OXB Oxford Biomedica plc | Initiated Coverage: Buy | 840p | 515p | n/a | 1 | May 3, 2023 | |
| CRSP CRISPR Therapeutics AG | Reiterated: Buy | $112 → $107 | $54.09 | n/a | 6 | Aug 8, 2022 |
Editas Medicine
Aug 18, 2026
Initiated Coverage: Buy
Price Target: $6
Current: $2.51
Upside: +139.04%
PMV Pharmaceuticals
Aug 17, 2026
Reiterated: Buy
Price Target: $3
Current: $1.36
Upside: +120.59%
Turn Therapeutics
Aug 13, 2026
Reiterated: Buy
Price Target: $16
Current: $13.04
Upside: +22.70%
Capricor Therapeutics
Jul 30, 2026
Downgraded: Hold
Price Target: n/a
Current: $8.71
Upside: -
Beam Therapeutics
Aug 19, 2025
Reiterated: Buy
Price Target: n/a
Current: $24.23
Upside: n/a
Intellia Therapeutics
May 29, 2025
Reiterated: Buy
Price Target: $65
Current: $11.42
Upside: n/a
Legend Biotech
May 13, 2025
Reiterated: Buy
Price Target: $83 → $55
Current: $18.62
Upside: n/a
Caribou Biosciences
Nov 8, 2023
Initiated Coverage: Hold
Price Target: n/a
Current: $1.23
Upside: n/a
Oxford Biomedica plc
May 3, 2023
Initiated Coverage: Buy
Price Target: 840p
Current: 515p
Upside: n/a
CRISPR Therapeutics AG
Aug 8, 2022
Reiterated: Buy
Price Target: $112 → $107
Current: $54.09
Upside: n/a